Summary

The 7 major nasopharyngeal cancer markets reached a value of US$ 858.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,075.5 Million by 2034, exhibiting a growth rate (CAGR) of 2.07% during 2024-2034.

The nasopharyngeal cancer market has been comprehensively analyzed in IMARC's new report titled "Nasopharyngeal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Nasopharyngeal cancer is a rare form of neck and head cancer that affects the nasopharynx, which is the upper part of the throat lying behind the nose. Depending on the size, location, extent, and severity of the tumor, the cancer is staged, ranging from 0-4. In several cases, people suffering from this ailment may experience a non-painful lump on the back of the neck. The other common symptoms include tinnitus, ringing in the ears, hearing loss, headaches, nasal stuffiness, difficulty opening the mouth, nosebleeds, ear infections, facial pain and numbness, trouble breathing or speaking, a feeling of fullness in the ear, etc. The diagnosis of nasopharyngeal cancer is based on a review of the patient's symptoms, medical history, hearing tests, and a complete physical exam. A healthcare professional may visually examine the nasopharynx, head, neck, lymph nodes, and facial muscles to detect any abnormalities or indications of cancer. Various diagnostic procedures, including computed tomography (CT) scan, positron emission tomography (PET) scan, magnetic resonance imaging (MRI), biopsy, etc., are utilized to further evaluate the extent of disease among patients.

The rising cases of Epstein-Barr virus infections, which can alter the DNA of cells in the nasopharynx, causing cells to grow and divide uncontrollably, are primarily driving the nasopharyngeal cancer market. In addition to this, the increasing incidences of several associated risk factors, such as regular consumption of salt-cured meat and fish, cigarette smoking, excessive alcohol intake, family history, etc., are also bolstering the market growth. Furthermore, the widespread adoption of concurrent chemoradiotherapy for the treatment of loco-regionally advanced disease is acting as another significant growth-inducing factor. This therapy approach aids in the substantial shrinkage of cancer cells, improves local tumor control, and promotes patient survival. Additionally, the escalating demand for immunotherapy, which boosts the body's defense mechanism to specifically detect and fight unhealthy cells, is also creating a positive outlook for the market. Moreover, the emerging popularity of proton therapy, since it involves the application of proton beams on tumors with greater sparing of exposure to normal tissues and minimum treatment-related toxicities, is expected to drive the nasopharyngeal cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the nasopharyngeal cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for nasopharyngeal cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nasopharyngeal cancer market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the nasopharyngeal cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the nasopharyngeal cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current nasopharyngeal cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the nasopharyngeal cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the nasopharyngeal cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the nasopharyngeal cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of nasopharyngeal cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of nasopharyngeal cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of nasopharyngeal cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with nasopharyngeal cancer across the seven major markets?
What is the size of the nasopharyngeal cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of nasopharyngeal cancer?
What will be the growth rate of patients across the seven major markets?

Nasopharyngeal Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for nasopharyngeal cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the nasopharyngeal cancer market?
What are the key regulatory events related to the nasopharyngeal cancer market?
What is the structure of clinical trial landscape by status related to the nasopharyngeal cancer market?
What is the structure of clinical trial landscape by phase related to the nasopharyngeal cancer market?
What is the structure of clinical trial landscape by route of administration related to the nasopharyngeal cancer market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Nasopharyngeal Cancer - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Nasopharyngeal Cancer - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Nasopharyngeal Cancer - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Nasopharyngeal Cancer - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Nasopharyngeal Cancer - Unmet Needs

10 Nasopharyngeal Cancer - Key Endpoints of Treatment

11 Nasopharyngeal Cancer - Marketed Products
11.1 List of Nasopharyngeal Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Nasopharyngeal Cancer - Pipeline Drugs
12.1 List of Nasopharyngeal Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Spartalizumab - Novartis Oncology
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Pembrolizumab - Merck & Co
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Nanatinostat - Viracta Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Sintilimab - Eli Lilly and Company/Innovent Biologics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Nasopharyngeal Cancer - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Nasopharyngeal Cancer – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Nasopharyngeal Cancer - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Nasopharyngeal Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Nasopharyngeal Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Nasopharyngeal Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Nasopharyngeal Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Nasopharyngeal Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Nasopharyngeal Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Nasopharyngeal Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Nasopharyngeal Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Nasopharyngeal Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Nasopharyngeal Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Nasopharyngeal Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Nasopharyngeal Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Nasopharyngeal Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Nasopharyngeal Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Nasopharyngeal Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Nasopharyngeal Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Nasopharyngeal Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Nasopharyngeal Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Nasopharyngeal Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Nasopharyngeal Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Nasopharyngeal Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Nasopharyngeal Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Nasopharyngeal Cancer - Access and Reimbursement Overview

16 Nasopharyngeal Cancer - Recent Events and Inputs From Key Opinion Leaders

17 Nasopharyngeal Cancer Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Nasopharyngeal Cancer Market – Strategic Recommendations

19 Appendix